Artiva Biotherapeutics (ARTV) Interest Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Interest Expenses data on file, last reported at $11.7 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 29.36% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $11.7 million, a 29.36% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 45.5% from the prior year.
• Interest Expenses for Q1 2026 stood at $11.7 million, up from $412000.0 in the prior quarter.
• Over the last five years, Interest Expenses for ARTV reached as high as $17.3 million in Q3 2024 and fell as low as $214000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $9.2 million across 4 years, with a median of $11.7 million in 2026.
• Across the five-year window, Interest Expenses jumped 3226.17% in 2024 and tumbled 94.21% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $214000.0 in 2023, then soared by 3226.17% to $7.1 million in 2024, then tumbled by 94.21% to $412000.0 in 2025, then soared by 2734.95% to $11.7 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $11.7 million in Q1 2026, $412000.0 in Q4 2025, and $1.8 million in Q3 2025.